NasdaqGS:RGENLife Sciences
Repligen (RGEN) Stock May Trade At Fair Value But At A Sales Premium
Repligen stock is coming off a mixed five year stretch, with the share price down 27.3% over that period, while current valuation checks send a cautious signal that the stock is not obviously cheap or excessively stretched around its estimated intrinsic value from a Discounted Cash Flow (DCF) view.
Over five years, Repligen shares have declined 27.3%. This asks investors to judge whether the current price fairly reflects what the business can deliver next.
Expectations for Repligen’s ability...